PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Summary

This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and for 3 consecutive days after autologous PBSCT for treating oral mucositis in patients with NHL and MM who have received high-dose conditioning chemotherapy.

Timeline

Start

2006-04

Primary completion

2007-04

Completion

2007-05

Drugs

Indications